Tenderwize
Zurück zur Suche

Open-House contract for Bimatoprost/Timolol eye drops

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 127 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The notice says offers/contracts cannot be submitted through the procurement portal and must instead be sent by email w...

Participation is limited to pharmaceutical undertakings meeting AMG seat and authorisation requirements for the specifi...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of pharmaceutical rebate contracts under Section 130a(8) SGB V for Bimatoprost/Timolol eye drops in single-dose pipettes.
  • Open-House model with uniform terms; no individual contract negotiations.
Vollständige Zusammenfassung anzeigen

This is a German Open-House pharmaceutical supply arrangement for Bimatoprost/Timolol eye drops in single-dose pipettes, led by Techniker Krankenkasse with HEK as a participating buyer. It is not a classic award procedure: no individual negotiations, no exclusivity, and contract entry is possible throughout the contract period if eligibility conditions are met. The notice and XML indicate electronic submission via the portal is not allowed; contracts must be submitted by email with qualified electronic signature or by post. No contract value is stated.

Risiken

The notice says offers/contracts cannot be submitted through the procurement portal and must instead be sent by email w...

Participation is limited to pharmaceutical undertakings meeting AMG seat and authorisation requirements for the specifi...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Bidder must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Bidder must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Bidder must hold a valid marketing authorisation for the contract medicinal product(s) or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House contract for Bimatoprost/Timolol eye drops

Open-House pharmaceutical rebate contract for the fixed medicinal product combination Bimatoprost/Timolol in the form of single-dose eye drops. Scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Dec 2024 - Dec 2026

Kategorie

Pharmaceutical products

Frist

Deadline Dec 29, 2026

Vergabedetails

Veröffentlichungsdatum
17 Nov 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
702294-2024

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3